Reviewing Scienture (SCNX) & The Competition

Scienture (NASDAQ:SCNX) is one of 248 public companies in the “MED – DRUGS” industry, but how does it contrast to its peers? We will compare Scienture to related companies based on the strength of its dividends, earnings, profitability, risk, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Scienture and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	-10,364.22%	-24.47%	-19.30%
Scienture Competitors	-19,411.49%	-96.06%	-16.45%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Scienture and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	0	0	1.00
Scienture Competitors	1956	3689	9728	395	2.54

As a group, “MED – DRUGS” companies have a potential upside of 74.68%. Given Scienture’s peers stronger consensus rating and higher possible upside, analysts plainly believe Scienture has less favorable growth aspects than its peers.

Insider and Institutional Ownership

5.7% of Scienture shares are held by institutional investors. Comparatively, 43.8% of shares of all “MED – DRUGS” companies are held by institutional investors. 21.4% of Scienture shares are held by company insiders. Comparatively, 13.4% of shares of all “MED – DRUGS” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Scienture and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Scienture	$128,202.00	$9.07 million	-0.27
Scienture Competitors	$30.17 billion	$57.36 million	3.48

Scienture’s peers have higher revenue and earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Scienture has a beta of 3.04, meaning that its share price is 204% more volatile than the S&P 500. Comparatively, Scienture’s peers have a beta of 1.27, meaning that their average share price is 27% more volatile than the S&P 500.

Summary

Scienture peers beat Scienture on 9 of the 13 factors compared.

Scienture Company Profile

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.